InvestorsHub Logo
Followers 269
Posts 8491
Boards Moderated 0
Alias Born 10/05/2010

Re: Chuckles759 post# 268

Monday, 08/29/2022 4:04:54 PM

Monday, August 29, 2022 4:04:54 PM

Post# of 278
I saw in the latest Q FINRA is not letting them change the name of the company to Rovida Therapeutics, does not sound like there is any recourse left either.......any merger or acquisition would likely be blocked by FINRA as well.....not many options left here but to sell this or give up on it completely.

On October 21, 2021, the Company submitted a Company Related Action Notification in accordance with Financial Industry Regulatory Authority (“FINRA”) Rule 6490 in connection with a proposed change of the Company’s name to “Rovida Therapeutics, Inc.,” the redomicile of the Company from Nevada to Delaware and a change in the Company’s ticker symbol (the “Corporate Actions”). The Corporate Actions have been approved by the board of directors of the Company and by Phoenixus as the holder of majority of the outstanding shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”). The Company’s application for FINRA approval of the Corporate Actions was denied by FINRA’s Department of Market Operations due to Phoenixus’s former association with Martin Shkreli as disclosed in the Company’s 2021 Form 10-K. The Company appealed FINRA’s determination to a subcommittee of FINRA’s Uniform Practice Code Committee, and on July 28, 2022, the Company’s appeal was denied by such subcommittee. As a result, the Corporate Actions will not be implemented, and given the appeal decision, the Company anticipates that it will take no further action on the Corporate Actions at this time.